Growing with Cerebral Palsy: Implementing Timely Multidisciplinary Strategies for the Transition of Care is organized by freeCME.com. This Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Released On: Apr 22, 2019
Expires On: Apr 22, 2020
This initiative is intended for pediatricians, neurologists, physiatrists, nurses, behavioral specialists, social workers, and other healthcare providers who care for patients with cerebral palsy (CP). No prerequisites required.
Cerebral palsy (CP) requires management across a patient’s lifespan. While CP is not a progressive disease, it is not unchanging. However, the care and rehabilitation of patients with CP are often front-loaded in early childhood, decreasing for older children and teens, and are limited or absent for adults. The transition to adulthood for a patient with CP is a complex process extending over several years. Failure to successfully transition to adulthood may negatively affect independence, employment, and quality of life.
Spasticity and dystonia are present in the majority of patients with CP and are problematic for many. Management of CP patients’ spasticity and dystonia is achieved via a multimodal approach, and therapeutic advances have dramatically prolonged life expectancy, improving the ability of CP patients to lead functional adult lives. Approval of the first botulinum toxin (BoNT) in 2016 for use in pediatric patients with CP to manage lower limb spasticity represents a major milestone in the management this patient population. This engaging enduring activity, led by an expert in physiatry, will review the multidisciplinary opportunities to address the gaps in care during the transition to adulthood as well as the pharmacological advances, particularly of BoNT therapy, as part of multimodal CP treatment.
The goal of this activity is to provide pediatricians, neurologists, physiatrists, nurses, behavioral specialists, social workers, and other healthcare providers who care for patients with CP with up-to-date information on BoNT pharmacotherapy options for CP management and tools and practical strategies to effectively incorporate transition programs into CP care paradigms.
Upon completion of this activity, participants should be able to:
• REVIEW pharmacological advances, particularly botulinum toxin (BoNT) therapy, as part of multimodal CP treatment and its impact on transition of care.
• RECOGNIZE unmet patient needs related to individualized CP transition and opportunities to address them.
• DEVELOP multidisciplinary strategies to successfully identify and implement the components of effective CP transition programs.